Floatz logo

Amylin

Obesity & Overweight

University Hospital, Gentofte, Copenhagenprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Obesity & Overweight cohort.

Asset / SponsorPhaseRating
Calcipotriene
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BB
bio101
Biophytis
Phase 2CCC
DWC202503
Daewoong Pharmaceutical Co. LTD.
Phase 1CC
TIX100
TIXiMED, Inc.
Phase 1CC
DWC202502
Daewoong Pharmaceutical Co. LTD.
Phase 1CC

View all 11 →

Same molecule, other indications

Amylin is also rated in:

Headache Disorders, PrimaryDormant
D
Indicative ·
30 / 100
View asset →
Headache DisordersDormant
D
Indicative ·
30 / 100
View asset →
nervous system disorderDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →